Archivel Farma's TB vaccine may cut treatment time from nine months to one

Spanish firm Archivel Farma announced during the BIO Convention taking place in Chicago, USA, that its breakthrough treatment for tuberculosis (TB) will shortly move into Phase II clinical trials.

The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and health care costs, by preventing re-infection during the eradication process. The company expects commercial availability of its product in 2015.

It has now been discovered that TB does not lie "dormant" but is actually waging a constant war with the host, constantly re-infecting the lungs. Provided that the host is healthy, it has the upper hand and usually keeps the TB in check - LTBI. TB is particularly tricky to eliminate as it can be either replicating, when it can be killed by the antibiotics, or non-replicating when antibiotics are useless. The long, nine month course of antibiotics is needed to ensure that all traces of the non-replicating form are eliminated from the lungs. Further details can be found at http://www.archivelfarma.com/hipotesi_an.html